The balance of host immunocompetence in chemical carcinogenesis and "nonspecific" immunotherapy.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology; D000818:Animals; D000951:Antigens, Neoplasm; D000961:Antilymphocyte Serum / Q000494:pharmacology; D001500:BCG Vaccine; D006224:Cricetinae; D006168:Guinea Pigs; D007109:Immunity / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007167:Immunotherapy; D007519:Isoantigens; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000139:chemically induced*; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D000951:Antigens, Neoplasm; D000961:Antilymphocyte Serum; D001500:BCG Vaccine; D007519:Isoantigens; D015127:9,10-Dimethyl-1,2-benzanthracene